Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation

* Company reduces the maximum aggregate payments under its royalty financing agreement from $125 million to $65 million

* Company accelerated payment of $42.6 million upfront, bringing total payments made to date to $50 million, a full return of NQ Project Phoebus, L.P.’s invested capital, with up to $15 million of additional royalty-based payments to follow